Lynn Anne Bristol

Array ( [id] => 7579628 [patent_doc_number] => 20110293511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-01 [patent_title] => 'SPECIFIC BINDING PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/078781 [patent_app_country] => US [patent_app_date] => 2011-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 147 [patent_figures_cnt] => 147 [patent_no_of_words] => 85755 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13078781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9843641 [patent_doc_number] => 08945552 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-03 [patent_title] => 'Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies' [patent_app_type] => utility [patent_app_number] => 13/071127 [patent_app_country] => US [patent_app_date] => 2011-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 27367 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13071127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9427063 [patent_doc_number] => 08703133 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-04-22 [patent_title] => 'Antibody variants' [patent_app_type] => utility [patent_app_number] => 13/052982 [patent_app_country] => US [patent_app_date] => 2011-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 24515 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13052982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10057329 [patent_doc_number] => 09096673 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-08-04 [patent_title] => 'IL-17 receptor A antigen binding proteins' [patent_app_type] => utility [patent_app_number] => 13/045308 [patent_app_country] => US [patent_app_date] => 2011-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 29 [patent_no_of_words] => 72212 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13045308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6014841 [patent_doc_number] => 20110223164 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-15 [patent_title] => 'BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/039097 [patent_app_country] => US [patent_app_date] => 2011-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 55667 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0223/20110223164.pdf [firstpage_image] =>[orig_patent_app_number] => 13039097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5969094 [patent_doc_number] => 20110150905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-23 [patent_title] => 'HUMAN ANTIBODIES TO HUMAN DELTA LIKE LIGAND 4' [patent_app_type] => utility [patent_app_number] => 13/034761 [patent_app_country] => US [patent_app_date] => 2011-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15942 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0150/20110150905.pdf [firstpage_image] =>[orig_patent_app_number] => 13034761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6080138 [patent_doc_number] => 20110142852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'MULTISPECIFIC ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/030760 [patent_app_country] => US [patent_app_date] => 2011-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 75 [patent_figures_cnt] => 75 [patent_no_of_words] => 56465 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20110142852.pdf [firstpage_image] =>[orig_patent_app_number] => 13030760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6080300 [patent_doc_number] => 20110142919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatment and Diagnosis of Cancer' [patent_app_type] => utility [patent_app_number] => 13/030563 [patent_app_country] => US [patent_app_date] => 2011-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33671 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20110142919.pdf [firstpage_image] =>[orig_patent_app_number] => 13030563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6084411 [patent_doc_number] => 20110144186 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'SSX-2 PEPTIDES PRESENTED BY HLA CLASS II MOLECULES' [patent_app_type] => utility [patent_app_number] => 13/028953 [patent_app_country] => US [patent_app_date] => 2011-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 22932 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0144/20110144186.pdf [firstpage_image] =>[orig_patent_app_number] => 13028953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9244813 [patent_doc_number] => 08609092 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-17 [patent_title] => 'Antibody drug conjugates (ADC) that bind to 161P2F10B proteins' [patent_app_type] => utility [patent_app_number] => 13/022905 [patent_app_country] => US [patent_app_date] => 2011-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 24 [patent_no_of_words] => 38415 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13022905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5937991 [patent_doc_number] => 20110213127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-01 [patent_title] => 'METHODS FOR USING AND IDENTIFYING MODULATORS OF DELTA-LIKE 4' [patent_app_type] => utility [patent_app_number] => 13/021617 [patent_app_country] => US [patent_app_date] => 2011-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 23016 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0213/20110213127.pdf [firstpage_image] =>[orig_patent_app_number] => 13021617 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6046765 [patent_doc_number] => 20110206700 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-25 [patent_title] => 'ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/019478 [patent_app_country] => US [patent_app_date] => 2011-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 18402 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0206/20110206700.pdf [firstpage_image] =>[orig_patent_app_number] => 13019478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10863443 [patent_doc_number] => 08889133 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-18 [patent_title] => 'Methods of treating diabetes with Dll4 antagonists' [patent_app_type] => utility [patent_app_number] => 13/015652 [patent_app_country] => US [patent_app_date] => 2011-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 14009 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13015652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10136013 [patent_doc_number] => 09169326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-27 [patent_title] => 'Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers' [patent_app_type] => utility [patent_app_number] => 13/012679 [patent_app_country] => US [patent_app_date] => 2011-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 26649 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13012679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8532931 [patent_doc_number] => 08309084 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-11-13 [patent_title] => 'Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis' [patent_app_type] => utility [patent_app_number] => 13/009757 [patent_app_country] => US [patent_app_date] => 2011-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 19885 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13009757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6054592 [patent_doc_number] => 20110110952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-12 [patent_title] => 'NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 184P1E2 USEFUL IN TREATMENT AND DETECTION OF CANCER' [patent_app_type] => utility [patent_app_number] => 12/985245 [patent_app_country] => US [patent_app_date] => 2011-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 68187 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0110/20110110952.pdf [firstpage_image] =>[orig_patent_app_number] => 12985245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10594507 [patent_doc_number] => 09315581 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-19 [patent_title] => 'Immuno-conjugates and methods for producing them' [patent_app_type] => utility [patent_app_number] => 13/383836 [patent_app_country] => US [patent_app_date] => 2010-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 51 [patent_no_of_words] => 60120 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13383836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10115770 [patent_doc_number] => 09150641 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-10-06 [patent_title] => 'Sequence dependent aggregation' [patent_app_type] => utility [patent_app_number] => 13/515428 [patent_app_country] => US [patent_app_date] => 2010-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 5838 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13515428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8920473 [patent_doc_number] => 08486404 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-07-16 [patent_title] => 'Antibody specifically binding to angiopoietin-2 and use thereof' [patent_app_type] => utility [patent_app_number] => 12/968500 [patent_app_country] => US [patent_app_date] => 2010-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 11493 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12968500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6159660 [patent_doc_number] => 20110159014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-30 [patent_title] => 'ANTI-HER2 ANTIBODY VARIANTS' [patent_app_type] => utility [patent_app_number] => 12/966834 [patent_app_country] => US [patent_app_date] => 2010-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 30935 [patent_no_of_claims] => 74 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0159/20110159014.pdf [firstpage_image] =>[orig_patent_app_number] => 12966834 [rel_patent_id] =>[rel_patent_doc_number] =>)